Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand
- PMID: 11221836
Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand
Abstract
Recently, Flt3 (Fms-like tyrosine kinase 3)-ligand has been identified as an important cytokine for the generation of professional antigen-presenting cells (APCs), particularly dendritic cells (DCs). A recombinant chimera of the extracellular domain of Flt3-ligand (FL) linked to a model antigen may potentially target the antigen to DCs and their precursor cells. Using human papillomavirus-16 E7 as a model antigen, we evaluated the effect of linkage to FL on the potency of antigen-specific immunity generated by naked DNA vaccines administered intradermally via gene gun. We found that vaccines containing chimeric FL-E7 fusion genes significantly increased the frequency of E7-specific CD8+ T cells relative to vaccines containing the wild-type E7 gene. In vitro studies indicated that cells transfected with FL-E7 DNA presented E7 antigen through the MHC class I pathway more efficiently than wild-type E7 DNA. Furthermore, bone marrow-derived DCs pulsed with cell lysates containing FL-E7 fusion protein presented E7 antigen through the MHC class I pathway more efficiently than DCs pulsed with cell lysates containing wild-type E7 protein. More importantly, this fusion converted a less effective vaccine into one with significant potency against established E7-expressing metastatic tumors. The FL-E7 fusion vaccine mainly targeted CD8+ T cells, and antitumor effects were completely CD4 independent. These results indicate that fusion of a gene encoding the extracellular domain of FL to an antigen gene may greatly enhance the potency of DNA vaccines via CD8-dependent pathways.
Similar articles
-
Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen.Cancer Res. 2001 May 1;61(9):3698-703. Cancer Res. 2001. PMID: 11325841
-
Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene.J Immunol. 2001 May 15;166(10):6218-26. doi: 10.4049/jimmunol.166.10.6218. J Immunol. 2001. PMID: 11342644
-
Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes.Cancer Res. 2003 May 15;63(10):2393-8. Cancer Res. 2003. PMID: 12750257
-
Modifying professional antigen-presenting cells to enhance DNA vaccine potency.Methods Mol Med. 2006;127:199-220. doi: 10.1385/1-59745-168-1:199. Methods Mol Med. 2006. PMID: 16988456 Review.
-
Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting.Methods. 2003 Nov;31(3):225-31. doi: 10.1016/s1046-2023(03)00136-1. Methods. 2003. PMID: 14511955 Review.
Cited by
-
New Approaches to Immunotherapy for HPV Associated Cancers.Cancers (Basel). 2011 Sep 2;3(3):3461-95. doi: 10.3390/cancers3033461. Cancers (Basel). 2011. PMID: 24212964 Free PMC article.
-
Perspectives for preventive and therapeutic HPV vaccines.J Formos Med Assoc. 2010 Jan;109(1):4-24. doi: 10.1016/s0929-6646(10)60017-4. J Formos Med Assoc. 2010. PMID: 20123582 Free PMC article. Review.
-
Novel vaccine development strategies for inducing mucosal immunity.Expert Rev Vaccines. 2012 Mar;11(3):367-79. doi: 10.1586/erv.11.196. Expert Rev Vaccines. 2012. PMID: 22380827 Free PMC article. Review.
-
Regulation of Immunogen Processing: Signal Sequences and Their Application for the New Generation of DNA-Vaccines.Acta Naturae. 2010 Apr;2(1):53-60. Acta Naturae. 2010. PMID: 22649628 Free PMC article.
-
Targeting vaccines to dendritic cells.Pharm Res. 2002 Mar;19(3):229-38. doi: 10.1023/a:1014474414097. Pharm Res. 2002. PMID: 11934227 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous